MedTrace Logo

A Study to Investigate the Safety and PK of VH4770359 in Healthy Participants

NCT07525544 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 214

Last updated 2026-04-13

No results posted yet for this study

Summary

VH4770359 (also known as GSK4770359) is an antiretroviral compound. This first-in-human study aims to evaluate the safety, tolerability, and pharmacokinetics (PK) of orally administered VH4770359 in healthy participants. The findings from this study will support the design of future clinical studies of VH4770359 in people living with HIV.

Conditions

  • HIV Infections

Interventions

DRUG

VH4770359

Participants will receive the assigned dose formulation of VH4770359 orally.

DRUG

Placebo

Participants will receive placebo to match the VH4770359 dose formulation.

DRUG

Midazolam

Participants receive 2 mg Midazolam on Days -1, Day 1 and Day 14.

Sponsors & Collaborators

  • ViiV Healthcare

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-04-07
Primary Completion
2027-05-05
Completion
2027-05-05
FDA Drug
Yes

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07525544 on ClinicalTrials.gov